A pilot comparative study of recombinant protein and whole-virus inactivated vaccines against porcine circovirus type 2 in conventionally reared pigs.
Porcine circovirus type 2 (PCV2) causes porcine circovirus-associated disease, which is characterized by systemic wasting syndrome, including respiratory problems worldwide. Most commercial PCV2 vaccines are derived from recombinant capsid protein or inactivated whole-virus. We compared average daily weight gain, interferon-γ, and neutralizing antibody levels of a recombinant protein vaccine and an inactivated whole-virus vaccine in a pilot study. Both PCV2 vaccines showed similar effect on immunity against PCV2 and a better average daily weight gain was found in both vaccinated groups compared to non-vaccinated animals.